Home
Applications
Indications
Business
EpiSwitch
®
Products
EpiSwitch
®
Explorer Kit
EpiSwitch
®
Service
Investors
Investors Overview
Results and Presentations
Share Price Information
Regulatory News
Board & Governance
Key Corporate Documents
AIM Rule 26
Email Alerts
Investor Contacts
News
About Us
History
Board of Directors
Management Team
Scientific Advisory Panel
Values
Careers
OBD and major US Pharma sign agreement to develop epigenetic knowledge and biomarkers to be used in the development of co-therapies for the treatment of acute myeloid leukemia (AML).
January 20, 2014
|
In
Milestones
|
By
Catia Gaspar
Prev
Next
Privacy Preference Center
Privacy Preferences